Additionally, a recent study found that PD treatment synergistically enhances cisplatin’s antitumor effects in non-small cell lung cancer (NSCLC) cells by increasing ROS production through NADPH oxidase 5 (NOX5) activation [31]. The gene discussed is NOX5; the disease is non-small cell lung carcinoma.